Effects of cannabis use on hospitalized patients with psychotic symptoms
Impact of Cannabis Consumption on the Course, Modalities of Hospitalization and the Short-term Prognosis of Inpatients Suffering From Psychotic Symptoms : Multicenter Comparative Observational Study
This study looks at how using cannabis affects the hospital stays and recovery of patients with psychotic symptoms to see if it makes things worse compared to those who don’t use cannabis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre hospitalier de Ville-Evrard, France Academic / other |
| Locations | 1 site (Neuilly-sur-Marne) |
| Trial ID | NCT06314204 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate how cannabis consumption affects the duration of hospitalization and the short- and medium-term prognosis of inpatients experiencing psychotic symptoms. It hypothesizes that patients using cannabis will have longer hospital stays, increased resistance to standard treatments, and more frequent relapses compared to non-cannabis users. The study will assess various factors, including the quality of therapeutic relationships and the presence of negative symptoms. By analyzing these aspects, the research seeks to provide insights into the implications of cannabis use in psychiatric care.
Who should consider this trial
Good fit: Ideal candidates for this study are hospitalized patients exhibiting psychotic symptoms, regardless of their mode of hospitalization, who are also cannabis users.
Not a fit: Patients with degenerative neurological conditions or those whose psychotic symptoms are secondary to other medical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could inform treatment approaches for patients with psychotic symptoms who use cannabis, potentially improving their care and outcomes.
How similar studies have performed: While some studies have indicated that cannabis use can worsen psychiatric conditions, this specific focus on hospitalized patients with psychotic symptoms is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Hospitalized in psychiatry regardless of the mode of hospitalization * With or without protective measures (guardianship or curatorship) * Presenting psychotic symptoms (schizophrenia, schizo affective disorder, thymic disorder with psychotic characteristic, psychotic disorder substance-induced, brief psychotic disorder, schizophrenic disorders, delirious disorders) * Members of the social security system * Enlightened information Exclusion Criteria: * Degenerative neurological pathologies or mental retardation * Psychotic disorders secondary to generalized medical conditions(epilepsy, delirium tremens, tumors, etc.) * Other psychiatric pathologies
Where this trial is running
Neuilly-sur-Marne
- unité de recherche clinique de l'E.P.S de Ville Evrard — Neuilly-sur-Marne, France (Recruiting)
Study contacts
- Study coordinator: RUSHEENTHIRA THAVASEELAN, MSc
- Email: r.thavaseelan@epsve.fr
- Phone: 0143083232
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.